细胞因子吸附对需ECMO的重症COVID-19肺炎患者无效且可能有害:CYCOV随机对照试验
CYCOV单中心开放标签随机对照试验纳入34例需静脉-静脉ECMO的重症COVID-19肺炎患者,1:1随机接受CytoSorb细胞因子吸附或不吸附。
要点
- 细胞因子吸附未降低72小时血清IL-6水平。
- 细胞因子吸附组30天生存率显著低于对照组。
- 不建议在COVID-19 ECMO支持早期使用细胞因子吸附。
核心结论
- 在需静脉-静脉ECMO的重症COVID-19患者中早期启动细胞因子吸附未降低血清IL-6,且对生存有负面影响。
- 细胞因子吸附不应在COVID-19 ECMO支持最初几天使用。
研究设计与样本
- 单中心、开放标签、随机、对照试验,在德国弗赖堡大学医学中心进行。
- 纳入34例需ECMO的成人重症COVID-19肺炎患者,1:1随机分配至CytoSorb细胞因子吸附组(17例)或不吸附对照组(17例)。
- CytoSorb装置接入ECMO回路,每24小时更换,72小时后移除。
- 主要终点为ECMO启动后72小时血清IL-6浓度,按意向性治疗分析;次要终点包括30天生存。
主要发现
- 两组各1例在72小时前死亡。
临床怎么用
- 对于需ECMO的重症COVID-19肺炎患者,不应在ECMO支持早期常规使用细胞因子吸附。
- 临床决策应权衡细胞因子吸附可能带来的生存损害。
局限性
- 单中心、开放标签设计,样本量小(34例)。
- 未报告其他次要终点和安全性数据的详细结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We sought to clarify the benefit of cytokine adsorption in patients with COVID-19 supported with venovenous extracorporeal membrane oxygenation (ECMO). METHODS: We did a single-centre, open-label, randomised, controlled trial to investigate cytokine adsorption in adult patients with severe COVID-19 pneumonia requiring ECMO. Patients with COVID-19 selected for ECMO at the Freiburg University Medical Center (Freiburg, Germany) were randomly assigned (1:1) to receive cytokine adsorption using the CytoSorb device or not. Randomisation was computer-generated, allocation was concealed by opaque, sequentially numbered sealed envelopes. The CytoSorb device was incorporated into the ECMO circuit before connection to the patient circuit, replaced every 24 h, and removed after 72 h. The primary endpoint was serum interleukin-6 (IL-6) concentration 72 h after initiation of ECMO analysed by intention to treat. Secondary endpoints included 30-day survival. The trial is registered with ClinicalTrials.gov (NCT04324528) and the German Clinical Trials Register (DRKS00021300) and is closed. FINDINGS: From March 29, 2020, to Dec 29, 2020, of 34 patients assessed for eligibility, 17 (50%) were treated with cytokine adsorption and 17 (50%) without. Median IL-6 decreased from 357·0 pg/mL to 98·6 pg/mL in patients randomly assigned to cytokine adsorption and from 289·0 pg/mL to 112·0 pg/mL in the control group after 72 h. One patient in each group died before 72 h. Adjusted mean log IL-6 concentrations after 72 h were 0·30 higher in the cytokine adsorption group (95% CI -0·70 to 1·30, p=0·54). Survival after 30 days was three (18%) of 17 with cytokine adsorption and 13 (76%) of 17 without cytokine adsorption (p=0·0016). INTERPRETATION: Early initiation of cytokine adsorption in patients with severe COVID-19 and venovenous ECMO did not reduce serum IL-6 and had a negative effect on survival. Cytokine adsorption should not be used during the first days of ECMO support in COVID-19. FUNDING: None.
引用
- Supady A, Weber E, Rieder M, et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. Lancet Respir Med. 2021. PMID: 34000236. doi:10.1016/S2213-2600(21)00177-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。